Skip to Content

Kinrix – Diphtheria, Tetanus Toxoid, and Acellular Pertussis and Inactivated Poliovirus Vaccine (DTaP / IPV)

Last Updated: July 26, 2011
Status: Resolved

Reason for the Shortage

GlaxoSmithKline could not provide a reason for the shortage.1

Estimated Resupply Dates

GlaxoSmithKline has available Kinrix vaccine in tip-lok syringes (NDC 58160-0812-52) and vials (NDC 58160-0812-11).1,2

Alternative Agents & Management

  • Kinrix is labeled to be given as a single dose to complete the 5th dose in the DTaP vaccine series and the 4th dose in the IPV series in children who are 4 to 6 years of age who received Infanrix (DTaP) or Pediarix (DTaP, recombinant Hepatitis B, and IPV) for the first 3 doses and Infanrix for the 4th dose.3
  • During this shortage, clinicians should use single component DTaP and IPV vaccines which remain available.4

Related Shortages


  1. GlaxoSmithKline (personal communications). April 28, July 13 and 26, 2011.
  2. GlaxoSmithKline Vaccines Supply Status (updated April 26, 2011)  
  3. GlaxoSMithKline. Kinrix (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine) Suspension for Intramuscular Injection. Research Triangle Park, NC: GlaxoSmithKLine; 2010.
  4. Department of Health and Human Services, Centers for Disease Control and Prevention. Recommended Immunization Schedule for Persons Aged 0 through 6 Years – United States 2011. Accessed April 28, 2011.


Updated July 26, 2011 by Jane Chandramouli, Pharm.D., Drug Information Specialist. Created April 28, 2011, by Erin R. Fox, Pharm.D., Manager, Drug Information Service Copyright 2011, Drug Information Service, University of Utah, Salt Lake City, UT.